GlassScriptPhysician profile
Deovrat Singh
NPI 1255330585
$4,956.36
in general payments reported to CMS, 2019-2025
41 companies · $662 in 2025
The $662 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,753 · 2020: $227 · 2021: $124 · 2022: $554 · 2023: $1,095 · 2024: $540 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,298.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $678.89 | 2019-2025 | |
| Heartflow, INC. | $637.30 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $357.72 | 2019-2024 | Xarelto |
| Pfizer INC. | $355.88 | 2019-2024 | |
| Boston Scientific Corporation | $346.24 | 2019-2025 | General - Therapies, Bodyguardian, Watchman Flx |
| Amgen INC. | $277.63 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $235.80 | 2019-2023 | Farxiga, Brilinta |
| Sanofi-Aventis U.S. LLC | $189.98 | 2019-2023 | |
| Abiomed | $183.08 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $166.11 | 2019-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $165.34 | 2019-2023 | Camzyos |
| Merck Sharp & Dohme LLC | $148.20 | 2022-2023 | Verquvo |
| Edwards Lifesciences Corporation | $117.94 | 2019 | |
| Shockwave Medical, INC | $83.54 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Altathera Pharmaceuticals LLC | $83.20 | 2023 | Sotalol Hydrochloride |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deovrat Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.